✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
MEK162 is an investigational drug.
There have been 67 clinical trials for MEK162. The most recent clinical trial was a Phase 3 trial, which was initiated on June 28th 2013.
The most common disease conditions in clinical trials are Melanoma, Neoplasms, and Colorectal Neoplasms. The leading clinical trial sponsors are Array BioPharma, Pfizer, and National Cancer Institute (NCI).
There are five hundred and seven US patents protecting this investigational drug and four international patents.
Recent Clinical Trials for MEK162
|A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors.||Pfizer||Phase 1|
|Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer||Pierre Fabre Medicament||Phase 2|
|Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer||National Cancer Institute (NCI)||Phase 1|
Top disease conditions for MEK162
Top clinical trial sponsors for MEK162
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|MEK162||See Plans and Pricing||Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity||The University of North Carolina at Chapel Hill (Chapel Hill, NC)||See Plans and Pricing|
|MEK162||See Plans and Pricing||Compounds and compositions as protein kinase inhibitors||Array BioPharma Inc. (Boulder, CO)||See Plans and Pricing|
|MEK162||See Plans and Pricing||Anti-CS1 antibodies and antibody drug conjugates||AbbVie Biotherapeutics Inc. (Redwood City, CA)||See Plans and Pricing|
|MEK162||See Plans and Pricing||.beta.-substituted .beta.-amino acids and analogs as chemotherapeutic agents and uses thereof||Quadriga Biosciences, Inc. (Los Altos, CA)||See Plans and Pricing|
|MEK162||See Plans and Pricing||Compounds for treatment of cancer||UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (Knoxville, TN)||See Plans and Pricing|
|MEK162||See Plans and Pricing||Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors||Array BioPharma Inc. (Boulder, CO)||See Plans and Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|MEK162||Australia||AU2015244171||2034-04-11||See Plans and Pricing|
|MEK162||Australia||AU2015244179||2034-04-11||See Plans and Pricing|
|MEK162||Canada||CA2945128||2034-04-11||See Plans and Pricing|
|MEK162||Canada||CA2945129||2034-04-11||See Plans and Pricing|
|MEK162||China||CN106414451||2034-04-11||See Plans and Pricing|
|MEK162||China||CN106459063||2034-04-11||See Plans and Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|